Roth/MKM Downgrades Avidity Biosciences (RNA) to Neutral
Tweet
Share
E-mailGet Alerts RNA Hot Sheet
Price: $11.57 +0.70%
Rating Summary:
11 Buy, 12 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 66
Rating Summary:
11 Buy, 12 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 66
Join SI Premium – FREE
Roth/MKM analyst Boobalan Pachaiyappan downgraded Avidity Biosciences (NASDAQ: RNA) from Buy to Neutral.
For an analyst ratings summary and ratings history on Avidity Biosciences click here. For more ratings news on Avidity Biosciences click here.
Shares of Avidity Biosciences closed at $49.15 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley Downgrades MapLight Therapeutics (MPLT) to Equalweight
- Curium said to near ~$7B acquisition of Lantheus - Bloomberg
- First Guaranty Bancshares, Inc. (FGBI) Tops Q2 EPS by 8c
Create E-mail Alert Related Categories
DowngradesRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
